LTZ Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
LTZ Therapeutics - overview
Established
2022
Location
Shenzhen, Guangdong, China
Primary Industry
Biotechnology
About
Established in 2022 and based in Shenzhen, China, LTZ Therapeutics operates as a biotechnology company that mainly provides immunotherapy original new drugs. It has branches in Redwood City and Heidelberg. The Co-founder and Chief Executive Officer, Robert Li, graduated from the University of Toronto and served as the President of the SOT Biotechnology Specialty Section. In April 2025, LTZ Therapeutics raised USD 40 million in series A+ funding led by new investor Boyu Capital.
The company focuses on the research and development of new immunotherapies, and its main products are based on the Myeloid Engager Platform. The product pipeline includes LTZ-301, LTZ-232, and LTZ-233. LTZ-301 is a new myeloid adapter bispecific antibody that can be used to treat relapsed or refractory non-Hodgkin's lymphoma. LTZ-232 and LTZ-233 are mainly targeted at solid tumors.
The original new drugs developed by the company are used in the fields of tumors and autoimmune diseases. The company generates revenue by providing original new drugs in the field of tumors and autoimmune diseases.
Current Investors
Qiming Venture Partners, K2VC, Tigermed
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.ltztherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.